2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/29/16REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors
ROCKVILLE, Md. and CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform (NAV), and Voyager Therapeutics, Inc. (Nasdaq:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announce... 
Printer Friendly Version
11/17/16REGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference
ROCKVILLE, Md., Nov. 17, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated (AAV) gene therapy based on its proprietary NAV® Technology Platform (NAV), today announced that President and CEO Kenneth T. Mills will present as part of the Gene Therapy Panel at the 28th Annual Piper Jaffray Healthcare Conference. The panel will take place on Wednesday, November 30, 2016 a... 
Printer Friendly Version
11/09/16REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
On track to dose first patient for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia by the end of 2016 Initiated manufacturing of material for Phase I clinical trial of RGX-314 for the treatment of wet age-related macular degeneration; IND filing planned for early 2017 Anticipate completion of new, advanced manufacturing and analytics lab by the end of 2016 $184.9 million in cash, cash equivalents and marketable securities as... 
Printer Friendly Version
11/02/16REGENXBIO to Host Conference Call on November 9 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 9, 2016 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2016 and recent operational highlights. To acce... 
Printer Friendly Version
10/04/16REGENXBIO to Present at the Jefferies Gene Editing and Gene Therapy Summit
ROCKVILLE, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that President and CEO Kenneth T. Mills will present a company overview at the Jefferies Gene Editing and Gene Therapy Summit. The company presentation will take place on Tuesday, October 11, 2016, at 1... 
Printer Friendly Version
09/13/16REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV® Gene Therapy in Neurodegenerative Diseases
Preclinical study of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I) demonstrates disease correction from a single administration of NAV AAV9 in a canine model; expected to help establish minimum effective dose in humans Preclinical study of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II) demonstrates disease correction from a single administration of NAV AAV9 in a mouse model Data support REGENXBIO’s efforts to advance a broad platform of NAV gene... 
Printer Friendly Version
09/07/16REGENXBIO to Participate in Global Healthcare Conferences
ROCKVILLE, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York. A live webcast of REGENXBIO’s presentation is scheduled to begin at 12:55 p.m. E... 
Printer Friendly Version
08/16/16Daniel Tassé Appointed to REGENXBIO Board of Directors
ROCKVILLE, Md., Aug. 16, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Daniel Tassé to its board of directors, effective August 15, 2016. "On behalf of the board of directors, I am pleased to welcome Daniel to REGENXBIO. Daniel’s extensive global execut... 
Printer Friendly Version
08/09/16REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
On track to enroll first patients for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia in the second half of 2016 Received FDA Rare Pediatric Disease Designation for RGX-121 for the treatment of Mucopolysaccharidosis Type II Entered into an exclusive license agreement with Biogen for the development of gene therapies for rare genetic vision disorders $198.7 million in cash, cash equivalents and marketable securities as of June 30, 2016 ... 
Printer Friendly Version
08/08/16Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors
ROCKVILLE, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Daniel J. Abdun-Nabi to its board of directors, effective as of August 5, 2016. "Dan is an experienced biopharmaceutical leader who brings to REGENXBIO more than 25 years of succes... 
Printer Friendly Version
08/02/16FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II)
ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-121, REGENXBIO’s investigational gene therapy product candidate for the treatment of Mucopolysaccha... 
Printer Friendly Version
08/01/16REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2016 and recent operational highlights. To access the li... 
Printer Friendly Version
07/05/16REGENXBIO Provides Update on Lead Gene Therapy Development Programs
Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia is actively recruiting and screening patients; expect to enroll first patient in second half of 2016 IND submission for RGX-314 for the treatment of wet age-related macular degeneration planned for first quarter of 2017 IND submissions for RGX-111 for the treatment of Mucopolysaccharidosis Type I and RGX-121 for the treatment of Mucopolysaccharidosis Type II planned for first half of 2017 ... 
Printer Friendly Version
05/16/16REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders
ROCKVILLE, Md., May 16, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on the NAV Technology Platform for the treatment of two rare genetic vision disorders. Th... 
Printer Friendly Version
05/05/16REGENXBIO Reports First Quarter 2016 Financial Results and Recent Operational Highlights
On track to initiate a Phase I/II clinical trial for RGX-501 for the treatment of homozygous familial hypercholesterolemia in the first half of 2016 Progressing toward filing an IND with the U.S. Food and Drug Administration for RGX-111 for the treatment of Mucopolysaccharidosis Type I in the first half of 2016; expect to initiate a Phase I/II clinical trial in the third quarter of 2016 First quarter 2016 cash burn of $7.8 million, with cash, cash equivalents and marketable securities of $... 
Printer Friendly Version
05/03/16REGENXBIO to Participate in May Investor Conferences
ROCKVILLE, Md., May 03, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that President and CEO Kenneth T. Mills will participate in the following May investor conferences. Bank of America Merrill Lynch 2016 Health Care Conference Dates: Tuesday, May 10 – Thursday, May 1... 
Printer Friendly Version
04/19/16Preclinical Data from REGENXBIO’s RGX-314 and RGX-121 Gene Therapy Programs to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
High expression of anti-VEGF antibody achieved in rhesus macaques with administration of RGX-314 for treatment of wet age-related macular degeneration Gene transfer mediated by RGX-121 shown to globally correct central nervous system manifestations of mucopolysaccharidosis Type II in animal models Data support FDA discussions on advancement of RGX-314 and RGX-121 into human clinical trials ROCKVILLE, Md., April 19, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a lead... 
Printer Friendly Version
03/03/16REGENXBIO Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Operational Progress
Entered 2016 in strong financial position with more than $215 million in cash, cash equivalents and marketable securities; on track to advance multiple lead gene therapy product candidate programs into clinic Active IND for RGX-501 for the treatment of homozygous familial hypercholesterolemia Received FDA orphan drug designation for RGX-121 for the treatment of mucopolysaccharidosis Type II; IND planned for first half of 2017 ROCKVILLE, Md., March 03, 2016 (GLOBE NEWSWIRE) -- REGENX... 
Printer Friendly Version
03/01/16REGENXBIO Announces Appointment of Faraz Ali as Chief Business Officer
ROCKVILLE, Md., March 01, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that Faraz Ali has been appointed as its Chief Business Officer. As a member of the leadership team, Mr. Ali is expected to oversee a wide range of functional responsibilities, including commercial and... 
Printer Friendly Version
02/29/16REGENXBIO Joins Organizations Worldwide to Recognize Rare Disease Day® 2016
ROCKVILLE, Md., February 29, 2016 -- REGENXBIO Inc. (Nasdaq: RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will join organizations worldwide to recognize Rare Disease Day® 2016, an annual event that seeks to raise awareness among the general public and stakeholders about rare diseases and their impact on pa... 
Printer Friendly Version
01/07/16REGENXBIO Provides Year-End 2015 Corporate Update
Company begins 2016 in strong financial position, on track to advance multiple lead gene therapy product candidate programs into clinic RGX-501 IND for treatment of homozygous familial hypercholesterolemia is active Five new NAV Vector licenses granted in the fourth quarter of 2015 ROCKVILLE, Md., Jan. 07, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associa... 
Printer Friendly Version